Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers

Research Site, Soweto

Research Site, Wollongong

Research Site, Box Hill

Research Site, Malvern

Research Site, South Brisbane

Research Site, Woolloongabba

Research Site, Greenslopes

Research Site, Benowa

Research Site, Buderim

Research Site, George

Research Site, Cape Town

Research Site, Christchurch

Research Site, Bangkok

Research Site, Bangkok

Research Site, Lublin

Research Site, Besançon

Research Site, Pamplona

Research Site, Bordeaux

Research Site, San Cristóbal de La Laguna

Research Site, Grenoble

Research Site, Khon Kaen

Research Site, Sumy

Research Site, Chiang Mai

Research Site, Chernivtsi

Research Site, Poznan

Research Site, Kharkiv

Research Site, Lyon

Research Site, Hat Yai

Research Site, Lodz

Research Site, Murmansk

Research Site, Saint Petersburg

Research Site, Saint Petersburg

Research Site, Volgograd

Research Site, Kazan'

Research Site, Chelyabinsk

Research Site, Tyumen

Research Site, Novosibirsk

Research Site, Omsk

Research Site, Nice

Research Site, Port Elizabeth

Research Site, Barcelona

Research Site, Madrid

Research Site, Málaga

Research Site, Seville

Research Site, Valencia

Research Site, Krakow

Research Site, Warsaw

Research Site, Pretoria